Page last updated: 2024-12-10
dmp 811
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
DMP 811: angiotensin II receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3081289 |
CHEMBL ID | 115021 |
SCHEMBL ID | 6556676 |
MeSH ID | M0227223 |
Synonyms (17)
Synonym |
---|
139964-19-5 |
4-ethyl-2-propyl-1-(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methylimidazole-5-carboxylic acid |
4-ethyl-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-carboxylic acid |
1h-imidazole-5-carboxylic acid, 4-ethyl-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- |
bdbm50049116 |
5-ethyl-2-propyl-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic acid |
5-ethyl-2-propyl-3-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic acid |
5-ethyl-2-propyl-3-(2''-tetrazol-1-yl-biphenyl-4-ylmethyl)-3h-imidazole-4-carboxylic acid |
dmp 811 |
CHEMBL115021 , |
dmp-811 |
5-ethyl-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid |
4-ethyl-2-propyl-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylic acid |
OFYWYKMCRWMPPQ-UHFFFAOYSA-N , |
SCHEMBL6556676 |
dmp811 |
DTXSID40161205 |
Research Excerpts
Overview
DMP 811 is a diacidic angiotensin II antagonist.
Excerpt | Reference | Relevance |
---|---|---|
"DMP 811 is a diacidic angiotensin II antagonist. " | ( Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist. Aungst, BJ; Blake, JA; Ensinger, CL; Hussain, MA; Pruitt, JR; Rogers, NJ; Saitoh, H, 1995) | 1.73 |
Effects
Excerpt | Reference | Relevance |
---|---|---|
"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing." | ( Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. Agra, AM; Ardecky, RJ; Carini, DJ; Chiu, AT; Huang, SM; Price, WA; Timmermans, PB; Wexler, RR; Wong, PC, 1995) | 1.23 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" It has relatively low oral bioavailability in rats." | ( Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist. Aungst, BJ; Blake, JA; Ensinger, CL; Hussain, MA; Pruitt, JR; Rogers, NJ; Saitoh, H, 1995) | 0.29 |
" The oral bioavailability of DMP 811 was low, but consistent across species." | ( Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee. Vyas, KP; Zhang, KE, 1995) | 0.94 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" A simple n-propyl ester was hydrolyzed very slowly (< 10% in 24 hr) in rat plasma in vitro, and after oral dosing in rats plasma prodrug concentrations were much greater than DMP 811 concentrations." | ( Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist. Aungst, BJ; Blake, JA; Ensinger, CL; Hussain, MA; Pruitt, JR; Rogers, NJ; Saitoh, H, 1995) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0060 | 0.0004 | 0.1555 | 3.8000 | AID37837 |
Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0060 | 0.0004 | 0.1334 | 3.8000 | AID37837 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (11)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID18173 | Oral bioavailability in dog | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. |
AID568790 | Displacement of radiolabeled angiotensin2 from angiotensin AT1 receptor in rat adrenal cortex membranes | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. |
AID182953 | In vivo inhibitory activity against angiotensin II induced pressor response in anesthetized normotensive rats | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1 | Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. |
AID39641 | In vitro for inhibition of [125I]-angiotensin II (0.1 nM) binding to angiotensin II receptor type 1 in membrane fractions of bovine adrenal cortex | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1 | Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. |
AID568868 | Antihypertensive activity in po dosed renal hypertensive rat model | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. |
AID37837 | Inhibitory activity against Angiotensin II receptor type 1 in rat adrenal membrane | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. |
AID18175 | Oral bioavailability in rat | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. |
AID568792 | Antihypertensive activity in iv dosed renal hypertensive rat model | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. |
AID568880 | Ratio of compound ED50 to losartan ED50 for po dosed renal hypertensive rat model | 2010 | Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 | Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. |
AID177204 | Oral effective dose required for lowering blood pressure in renal hypertensive rats (RHR) | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. |
AID177200 | Intravenous effective dose required for lowering blood pressure in renal hypertensive rats (RHR) | 1996 | Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 | Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (77.78) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.90) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (22.22%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (77.78%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |